Table 1 Comparison of clinical characteristics of MPP between the immunosuppressant and non-immunosuppressant groups.

From: Immunosuppression Reduces Lung Injury Caused by Mycoplasma pneumoniae Infection

  Non-immunosuppressant group (n = 789/3370) Immunosuppressant group (n = 19/201) P value
MP incidence, % 23.41 9.45 0.000
Age, years 3.57 ± 2.797 3.79 ± 2.76 0.222
Sex (male/female) 428/361 9/10 0.553
Complications 159 (20.15%) 3 (15.78%) 0.001
Severe cases 220 (27.8%) 0 (0%) 0.000
WBC × 109/L 9.80 ± 4.51 6.01 ± 7.26 0.000
Neutrophils × 109/L 5.46 ± 3.49 2.43 ± 2.46 0.001
Lymphocytes × 109/L 3.36 ± 2.55 2.81 ± 5.56 0.669
CRP, mg/L 16.32 ± 20.78 43.19 ± 44.34 0.043
LDH, IU/L 383.80 ± 216.16 297.18 ± 109.69 0.099
  1. MPP, Mycoplasma pneumoniae pneumonia; MP, Mycoplasma pneumoniae; WBC, white blood cells; CRP, C-reactive protein; LDH, L-lactate dehydrogenase. Data are presented as mean ± standard deviation or number (percentage).